Lynnet Koh, M.B.A.
Chairman, CEO & Founder

Ms. Koh is a serial entrepreuner/intrapreuner with extensive Senior and C-level executive experience in the biotech, wireless, internet, and consumer products industries. She has led top corporate priority major growth initiatives, created the vision, championed and led the successful development of major product/technology innovations and successful global market launch of best in class products that transformed various industries/markets and delivered over $2.5B in new revenues. Homes runs include the first Caller ID in the world (AT&T Bell Laboratories), the world’s first generation wireless systems that set the industry benchmarks for mobility, portability and quality (AT&T Bell Laboratories), first generation Voice over Internet System (Cisco Systems). Her core competencies and passion are that of leading mission impossible-type major technology innovation/new product development projects from idea to global commercialization, major revenue and market leadership achievement – and in the process, transforming the lives of people around the world and creating new markets and industries. In a general management capacity, she has built multiple teams and organizations from ground-up. Ms. Koh has also led numerous deals including, raising over $115MM for her various intrapreunerial/entrepreunerial startups, numerous M&A and licensing deals. MIT educated, she was in high potential executive leadership programs with industry leaders which provided her the hands on growth opportunity to demonstrate results in general management, brand management, sales leadership, new product development, product commercialization, P&L and market performance management.

Alan Lewis, Ph.D.
Board Member

Dr. Lewis is currently CEO and Director of Medistem, Inc. He was recently President, CEO and Chairman of Ambit BioSciences, and previously President and CEO of the Juvenile Diabetes Research Foundation and President, CEO and Director of Novocell, Inc. Prior to Novocell, Dr. Lewis served as CEO and Director of Signal Pharmaceuticals before its acquisition by Celgene, a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for cancer and immunological diseases, after which he served as President of the Signal Research Division at Celgene. Before joining Signal, Dr. Lewis held the position of Vice President of Research at Wyeth-Ayerst, where he spent 15 years leading research efforts in diabetes, CNS, cardiovascular, inflammatory, allergy, and bone metabolism diseases. Dr. Lewis currently serves as a Director of BioMarin Pharmaceutical, Inc. He holds a Ph.D. in pharmacology from the University of Wales in Cardiff and completed his postdoctoral training at Yale University.